Pingchuan Pharmaceutical Inc
Undervalued
Special Situation |
| Symbol: |
PGCN |
| 52 Week Range |
0.15 - 4.00 |
| Shares Float: |
25,000,000 |
| Current Price: |
$4.75 |
| 12 Mo.Target Price |
$26.00 |
| Last 5 days gain |
$3.40 | |
Breaking News
Alerts!
Big News
Expected Thursday
Jun 22
Value should
climb quickly! Be ready for the ride of your life, as
you can see so far
PR Newswire (Tue, Jun 14)
Pingchuan Signs Regional
Distribution Contract With Beijing Pingchuan Tianzhi Medical
Technology Development Center
EDGAR Online (Mon, May
23)
PINGCHUAN PHARMACEUTICAL INC Files
SEC form 10QSB, Quarterly Report
CORPORATE
PROFILE :
Pingchuan
Pharmaceutical Inc. (''PGCN'') is a modernized pharmaceutical
manufacturer with first-class medical R&D ability, pioneered
medicine products, and well-established marketing network. Since its
establishment, PGCN has focused its businesses on diabetes medicine
and its medical products. The products of PGCN include health care
products, varieties of medicine, as well as medical apparatus. Kang
Da Glycosuria Capsule is a successful product of PGCN for treating
diabetes, which was first developed in 1998 and introduced to the
market in 2001. PGCN has well-established marketing network and sale
branches, which include about 180,000 retail pharmacies/drugstores
across China, agency network in major cities like Beijing, Shanghai,
Guangzhou, and Xi'an, special counter sale at drug chain stores in
key regions, residence community clinic sale and promotion, as well
as internet marketing through the company's website. The marketing
network of PGCN covers more than 50% districts of China and exports
to US, Japan, Russia, and south-eastern Asia.
About Beijing
Pingchuan Tianzhi Medical Technology Development
Center
Beijing Pingchuan Tianzhi Medical Technology
Development is grouped under Harbin Pingchuan Pharmaceutical Co.,
Ltd. in Jan. 2000. It is a wholly-owned subsidiary of Harbin
Pingchuan Pharmaceutical Company. TIANZHI focuses on dealing with
self-produced products, as well as dealing & distributing other
medicines, health cares, pharmaceutical apparatuses and
international trade businesses TIANZHI was authorized as the
exclusive agent for the product of Kangda'an sugar capsule in
Beijing area. By the end of 2004, TIANZHI printed out its good
result that the total number of medicine bottles sold out was 26,000
and the sales revenue in 2004 was
RMB400,000.
PGCN is
getting ready to break out. We recommend this as a VERY strong
buy.
|